A Clinical Trial Assessing the Impact of Inhaled Insulin on Glucose Disposition

Pfizer

Status and phase: Terminated; Phase 3

Conditions: Diabetes Mellitus

Treatments: Drug: Regular Human Insulin; Drug: Inhaled Human Insulin

Study type: Interventional

Funder types: Industry

Identifiers

NCT00287066

A2171060

Details and patient eligibility

About

To assess the impact of inhalation of insulin on glucose disposition in patients with type 1 diabetes

Full description

The study was terminated on Oct. 28, 2007. The protocol was undergoing implementation and methodological issues with major revisions that qualified this trial as a new trial. Pfizer decided to cancel new trials because of the decision to withdraw Exubera due to lack of market performance and not for safety reasons.

Sex: All

Ages: 18 to 50 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Diabetes mellitus Type 1

Exclusion criteria

• Asthma, COPD
• Smoking

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)